Company: TDBCP
Filing Date: 2025-06-11
Form Type: 424B2
Source: 0001140361-25-022196
Chunk: 10

Company: TORONTO DOMINION BANK
Filing Date: 2025-06-11
Form: 424B2
Chunk 10
---
 an investment linked to companies that operate in multiple sectors. Adverse conditions in the biotechnology sector may reduce your return on the notes.

| Accelerated Return Notes® | TS-7 |

| Accelerated Return Notes®                           
 Linked to the SPDR®S&P®Biotech ETF due August, 2026 |

All of the stocks held by the Underlying Fund are issued by companies whose primary lines of business are directly associated with the biotechnology sector. The profitability of these companies is largely dependent on, among other things, demand for the companies’ products, regulatory influences on the biotechnology market (including healthcare reform and receipt of regulatory approvals and compliance with complex regulatory requirements), pricing and reimbursement from third party payors, continued innovation and successful development of new products, talent attraction and retention, maintaining intellectual property rights and industry competition. Any adverse developments affecting the biotechnology sector could adversely affect the price of the Underlying Fund and, in turn, the value of the notes. The sponsor or investment advisor of the Underlying Fund may adjust the Underlying Fund in a way that affects its prices, and the sponsor or investment advisor has no obligation to consider your interests. The sponsor or investment advisor of the Underlying Fund can add, delete, or substitute the components included in the Underlying Fund or make other methodological changes that could change its price. Any of these actions could adversely affect the value of your notes.

| Accelerated Return Notes® | TS-8 |

| Accelerated Return Notes®                           
 Linked to the SPDR®S&P®Biotech ETF due August, 2026 |

The Underlying Fund All disclosures contained in this term sheet regarding the Underlying Fund, including, without limitation, its make-up, method of calculation, and changes in its components, have been derived from publicly available sources. The information reflects the policies of, and is subject to change by, SSGA Funds Management, Inc., the advisor to the Underlying Fund (the “sponsor” or “SSGA”). The sponsor has no obligation to continue to publish, and may discontinue publication of, the Underlying Fund. The consequences of the sponsor discontinuing publication of the Underlying Fund are discussed in the section entitled “Description of ARNs —Anti-Dilution and Discontinuance Adjustments Relating to Underlying Funds” beginning on page PS-28 of product supplement EQUITY ARN-1. None of us, our affiliates, the calculation agents, MLPF&S or BofAS accepts any responsibility for the calculation, maintenance